The IGNITE trial: Participant recruitment lessons prior to SARS-CoV-2

Eric D. Vidoni, Amanda Szabo-Reed, Chaeryon Kang, Ashley R. Shaw, Jaime Perales-Puchalt, George Grove, Morgan Hamill, Donovan Henry, Jeffrey M. Burns, Charles Hillman, Arthur F. Kramer, Edward McAuley, Kirk I. Erickson

Research output: Contribution to journalArticlepeer-review


Full and diverse participant enrollment is critical to the success and generalizability of all large-scale Phase III trials. Recruitment of sufficient participants is among the most significant challenges for many studies. The novel SARS-CoV-2 coronavirus pandemic has further changed and challenged the landscape for clinical trial execution, including screening and randomization. The Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE) study has been designed as the most comprehensive test of aerobic exercise effects on cognition and brain health. Here we assess recruitment into IGNITE prior to the increased infection rates in the United States, and examine new challenges and opportunities for recruitment with a goal of informing the remaining required recruitment as infection containment procedures are lifted. The results may assist the design and implementation of recruitment for future exercise studies, and outline opportunities for study design that are flexible in the face of emerging threats.

Original languageEnglish (US)
Article number100666
JournalContemporary Clinical Trials Communications
StatePublished - Dec 2020


  • COVID-19
  • Cognition
  • Disparity
  • Enrollment
  • Exercise
  • Screen-fail

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'The IGNITE trial: Participant recruitment lessons prior to SARS-CoV-2'. Together they form a unique fingerprint.

Cite this